Daxor Corporation (NASDAQ:DXR) Sees Large Decline in Short Interest

Daxor Corporation (NASDAQ:DXR) was the target of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 1,276 shares, a decrease of 38.7% from the June 15th total of 2,083 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 3,122 shares, the days-to-cover ratio is currently 0.4 days.

Daxor Stock Performance

NASDAQ DXR opened at $10.57 on Thursday. The company has a 50-day simple moving average of $10.34 and a two-hundred day simple moving average of $11.26. Daxor has a 12-month low of $8.56 and a 12-month high of $14.76.

Daxor (NASDAQ:DXR) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.10) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Hedge Funds Weigh In On Daxor

Institutional investors and hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. purchased a new position in Daxor in the 2nd quarter worth approximately $86,000. Nano Cap New Millennium Growth Fund L P bought a new stake in Daxor in the fourth quarter valued at approximately $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new stake in shares of Daxor during the first quarter valued at approximately $245,000. Crescent Grove Advisors LLC purchased a new stake in shares of Daxor during the first quarter valued at approximately $104,000. Finally, Aristides Capital LLC bought a new position in shares of Daxor in the first quarter worth approximately $403,000. 1.34% of the stock is currently owned by institutional investors.

Daxor Company Profile

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.